11:59:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-14 Kvartalsrapport 2024-Q2
2024-03-07 X-dag ordinarie utdelning DEMANT 0.00 DKK
2024-03-06 Årsstämma 2024
2024-02-06 Bokslutskommuniké 2023
2023-08-15 Kvartalsrapport 2023-Q2
2023-03-09 X-dag ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 Årsstämma 2023
2023-02-07 Bokslutskommuniké 2022
2022-08-16 Kvartalsrapport 2022-Q2
2022-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-08-12 Kvartalsrapport 2021-Q2
2021-03-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-08-17 Kvartalsrapport 2020-Q2
2020-03-11 X-dag ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-03-20 X-dag ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-08-15 Kvartalsrapport 2018-Q2
2018-03-23 X-dag ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-08-14 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-28 X-dag ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 Årsstämma 2017
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-25 Split DEMANT 1:5
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-11-13 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-05-08 Kvartalsrapport 2014-Q1
2014-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2014-04-09 Årsstämma 2014
2014-02-27 Bokslutskommuniké 2013
2013-11-05 Kvartalsrapport 2013-Q3
2013-08-14 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-10 X-dag ordinarie utdelning DEMANT 0.00 DKK
2013-04-09 Årsstämma 2013
2013-02-26 Bokslutskommuniké 2012
2012-11-07 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-05-10 Kvartalsrapport 2012-Q1
2012-04-12 X-dag ordinarie utdelning DEMANT 0.00 DKK
2012-04-11 Årsstämma 2012
2012-02-29 Bokslutskommuniké 2011
2011-11-10 Kvartalsrapport 2011-Q3
2011-08-19 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-14 X-dag ordinarie utdelning DEMANT 0.00 DKK
2011-04-13 Årsstämma 2011
2010-11-16 Kvartalsrapport 2010-Q3
2010-04-08 X-dag ordinarie utdelning DEMANT 0.00 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Demant är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2024-03-06 16:33:35

6.3.2024 16:33:34 CET | Demant A/S | Decisions of general meeting

Company announcement no 2024-06

6 March 2024

Decisions of Annual General Meeting

 

Today, Demant A/S held its annual general meeting, which took place at the company’s premises, Kongebakken 9, 2765 Smørum, Denmark.

 

In his address, the Chair of the Board of Directors, Niels B. Christiansen, gave an account of the Group’s development in 2023. The report is available on www.demant.com. He said among other things:

 

“We can look back on a year where we achieved the best results in the history of the company, while also helping an incredible number of people by treating their hearing loss. We are extremely happy that already in February, we were able to announce another new and groundbreaking flagship product, Oticon Intent, which will support growth in 2024.

 

This underscores the value of our products and services and not least the positive contribution we make to society. It is also a testament to how our engaged employees work every day to realise our ambition to improve as many lives as possible. Our ambition and care for people’s hearing health and well-being go hand in hand with caring for society and the planet.”

 

All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:

 

  • The company’s Annual Report 2023 was approved, and the year’s profit, DKK 1,375 million, will be transferred to the company’s reserves.
  • The Remuneration Report for 2023 was approved.
  • The proposal for the Director’s fee to remain the same as in 2023 was adopted.
  • Niels B. Christiansen, Niels Jacobsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected to the Board of Directors.
  • The company’s auditors, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC), was re-elected. A proposal to the effect that in the future, PwC’s tasks will also include providing an opinion on the assurance of sustainability reporting in the management’s review was adopted.
  • The age limit in the Articles of Association will be removed.
  • The company’s share capital will be reduced by nominally DKK 569,929.60, corresponding to the company’s holding of treasury shares as of 5 February 2024, less shares to cover management's retention programme. The company’s holding of treasury shares was acquired during 2023 as part of the company’s share buy-back scheme. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 44,217,958.40.
  • Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.

 

After the general meeting, the Board of Directors elected Niels B. Christiansen Chair and Niels Jacobsen Vice Chair of the Board. Sisse Fjelsted Rasmussen continues as chair of the audit committee.

Pursuant to rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, Demant hereby provides the following information as follow-up on the Executive Board’s share-based programme, which is part of the Executive Board’s remuneration:

 

Description of the
programme

A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting. Please refer to the Remuneration Policy for a detailed description of the programme.

Vesting period

2024-2027, i.e. three years

Performance period

2024, i.e. one year (the first year of the vesting period)

Share price used for grant calculation

DKK 351.21, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2023.

Total number of RSUs granted

50,289

Theoretical market value of the programme

DKK 17,662,000 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.

 

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Henrik Axel Lynge Buchter, External Communication Manager

 

Contacts

  • Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.

Attachments